Limited predictive value of the gut microbiome and metabolome for response to biological therapy in inflammatory bowel disease.

Autor: Prins FM; Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.; Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Hidding IJ; Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Klaassen MAY; Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Collij V; Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Schultheiss JPD; Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, The Netherlands., Uniken Venema WTC; Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Bangma A; Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Aardema JB; Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Jansen BH; Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Mares WGN; Gastroenterology and Hepatology Department, Hospital Gelderse Vallei, Ede, The Netherlands., Witteman BJM; Gastroenterology and Hepatology Department, Hospital Gelderse Vallei, Ede, The Netherlands., Festen EAM; Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Dijkstra G; Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Visschedijk MC; Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Fidder HH; Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, The Netherlands., Vich Vila A; Department of Microbiology and Immunology, Rega Institute for Medical Research, Leuven, Belgium.; Center for Microbiology, VIB, Leuven, Belgium., Oldenburg B; Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, The Netherlands., Gacesa R; Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.; Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Weersma RK; Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.; Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Publikováno v: Gut microbes [Gut Microbes] 2024 Jan-Dec; Vol. 16 (1), pp. 2391505. Date of Electronic Publication: 2024 Aug 21.

Letter: loss of response to anti-TNFα agents depends on treatment duration in patients with inflammatory bowel disease-authors' reply.

Autor: Mahmoud R; Division of Internal Medicine and Dermatology, Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, The Netherlands., Schultheiss JPD; Division of Internal Medicine and Dermatology, Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, The Netherlands., Fidder HH; Division of Internal Medicine and Dermatology, Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, The Netherlands., Oldenburg B; Division of Internal Medicine and Dermatology, Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, The Netherlands.

Publikováno v: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2022 Feb; Vol. 55 (4), pp. 499-500.

Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease.

Autor: Mahmmod S; Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, the Netherlands., Schultheiss JPD; Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, the Netherlands., van Bodegraven AA; Department of Gastroenterology and Hepatology, Zuyderland Medisch Centrum, Sittard, the Netherlands., Dijkstra G; Department of Gastroenterology and Hepatology, University Medical Centre Groningen, Groningen, the Netherlands., Gilissen LPL; Department of Gastroenterology and Hepatology, Catharina Ziekenhuis, Eindhoven, the Netherlands., Hoentjen F; Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, the Netherlands., Lutgens MWMD; Department of Gastroenterology and Hepatology, Elisabeth TweeSteden Ziekenhuis, Tilburg, the Netherlands., Mahmmod N; Department of Gastroenterology and Hepatology, St. Antonius Ziekenhuis, Nieuwegein, the Netherlands., van der Meulen-de Jong AE; Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, the Netherlands., Smits LJT; Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, the Netherlands., Tan ACITL; Department of Gastroenterology and Hepatology, Canisius-Wilhelmina Ziekenhuis, Nijmegen, the Netherlands., Oldenburg B; Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, the Netherlands., Fidder HH; Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, the Netherlands.

Publikováno v: Inflammatory bowel diseases [Inflamm Bowel Dis] 2021 Nov 15; Vol. 27 (12), pp. 1954-1962.

Adherence to Adalimumab Was Not Improved by a Reminder-Based Intervention with an Electronic Needle Container.

Autor: Schultheiss JPD; Department of Gastroenterology and Hepatology, University Medical Center Utrecht, PO box L00.418, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands. j.p.d.schultheiss-7@umcutrecht.nl., Altena S; Department of Gastroenterology and Hepatology, University Medical Center Utrecht, PO box L00.418, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands., Clevers MR; Department of Gastroenterology and Hepatology, University Medical Center Utrecht, PO box L00.418, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands., Baas D; Department of Hospital Pharmaceutics, Meander Medical Center Amersfoort, Maatweg 3, 3812 TZ, Amersfoort, The Netherlands., Jharap B; Department of Gastroenterology and Hepatology, Meander Medical Center Amersfoort, Maatweg 3, 3812 TZ, Amersfoort, The Netherlands., Fidder HH; Department of Gastroenterology and Hepatology, University Medical Center Utrecht, PO box L00.418, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.

Publikováno v: Digestive diseases and sciences [Dig Dis Sci] 2021 May; Vol. 66 (5), pp. 1477-1487. Date of Electronic Publication: 2020 Jun 16.

Earlier discontinuation of TNF-α inhibitor therapy in female patients with inflammatory bowel disease is related to a greater risk of side effects.

Autor: Schultheiss JPD; Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, The Netherlands., Brand EC; Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, The Netherlands., Lamers E; Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, The Netherlands., van den Berg WCM; Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, The Netherlands., van Schaik FDM; Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, The Netherlands., Oldenburg B; Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, The Netherlands., Fidder HH; Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, The Netherlands.

Publikováno v: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2019 Aug; Vol. 50 (4), pp. 386-396. Date of Electronic Publication: 2019 Jul 16.